anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This prospective single arm study will be conducted within DUH Department of Radiology CT Imaging. The study team will enroll 50 patients with a history of axillary SLNP presenting for routine radiographic scan to undergo ipsilateral IV insertion. Patients will complete baseline bilateral arm volumetric measurements and self-reported symptom assessments. Patients will be followed every 3 months for 1-year duration for development of lymphedema. Patient acceptance or reluctance to ipsilateral IV access will be categorized at time of screening. Staff uptake on practice change will be assessed through medical record documentation for number, location, and factors affecting IV attempts and their perceptions of practice change and acceptance at the end of one year.

All participants will complete baseline measures: bilateral volumetric measurements and self-reported symptoms. Per DUH policy, participants will undergo SOC contralateral arm intravenous access attempt. After one failed attempt, ipsilateral intravenous access instead of pedal or neck access will be offered per research protocol. Nursing documentation will reflect the failed venipuncture and categorize a reason for the failed attempt. At the discretion of the treating radiologist, a participant who has a history of multiple failed IV placement attempts in the contralateral arm may proceed to IV placement in the ipsilateral arm on the first attempt.

Patients with successful ipsilateral intravenous access will be provided a patient education sheet describing signs and symptoms that should be reported to the study team. All participants will be contacted by the study team at twelve week intervals for 12 months after their radiology encounter for completion of symptom assessments. If a subject reports new signs or symptoms of lymphedema during follow-up, a clinic appointment for volumetric measurements and thorough evaluation will occur within 2 weeks; findings will be discussed with their physician. Participants will undergo bilateral volumetric measurements, symptom assessments, and perceptions of the ipsilateral IV access protocol at the end of one year.
A reduced, adaptive study design will be used to compare the PK of miricorilant between participants with normal hepatic function and participants with hepatic impairment according to the Child-Pugh (CP) classification. Initially, participants with moderate hepatic impairment will be enrolled. Since indications for the development of miricorilant include participants with NASH, 3 or 4 of these participants will have NASH. Healthy control participants will be selected matched to these participants with moderate hepatic impairment according to gender, age (± 10 years), and weight (± 20 %) using a mean matching procedure. Based on the observed effect of moderate hepatic impairment on the miricorilant PK profile following an interim PK analysis, an optional group of participants with mild hepatic impairment may be evaluated. This optional group, matched to the participants with moderate hepatic impairment using the same procedure, will be enrolled to evaluate the effect of mild hepatic impairment on miricorilant PK.
PURPOSE:To provide a cosmetic containing the extract of ENMEIPI (Sapindus mukurossi Gaertn.), and having excellent effect to cure the wound, prevent and improve the chapping of the skin, and prevent the aging by suppressing the loosening of the skin and the loss of the gloss of the skin. CONSTITUTION:The fruit of ENMEIPI is refluxed in a solvent (e.g. water, a lower alcohol such as methanol, hydrated lower alcohol, etc.) under heating, and the extract liquid is filtered and concentrated to obtain the extract of ENMEIPI. The extract may be adsorbed in a highly porous polymer and eluted with methanol. The obtained extract of ENMEIPI is added to a cosmetic in an amount of 0.00005-10wt%, preferably 0.0001-5wt%. Various other components used in cosmetics and pharmaceuticals, etc., may be used in addition to the above essential component, and above all, a remarkable effect can be exhibited by the addition of L-ascorbic acid or its ester.
PURPOSE:To serve the purpose for prevention or decision of vaccine effect in making the measurement in any medical facilities safely and quickly possible, by using a virus lost the vital power of an infectious property by a virus inactivating agent as an antigen and measuring a virus neutralization antibody in blood serum to be inspected. CONSTITUTION:A virus inactivating agent such as beta-propiolactone, KIO4, acridine etc. or a virus lost the vital power of an infectious property by ultraviolet rays, is used for an antigen. For example, a herpes simple virus is inactivated and is inoculated said virus into a 3T3 cell of a mouse and then, a floating liquid of the cell is made after cultivating for several housrs. On the one hand, inactivated virus mixed and reacted with an equvalent immune serum or diluted system of a serum of a patient, is inoculated into the 3T3 cell and the floating liquid of the cell is made after cultivating for several hours. Inactivated virus inoculated cell floating liquid conheres the cell by 10- 30mug/ml concanavaline A, but the 3T3 cell floating liquid inoculated the inactive virus which is mixed with the immune serum or the serum of the patient, not coheres. The cell inoculated the inactive virus which is reacted with the serum of a normal man, coheres. Hereby, safe measurement is performed because of the active virus is not used.
Overdoses of esmolol hydrochloride can cause cardiac arrest. In addition, overdoses can produce bradycardia, hypotension, electromechanical dissociation and loss of consciousness. Cases of massive accidental overdoses of esmolol hydrochloride have occurred due to dilution errors. Some of these overdoses have been fatal while others resulted in permanent disability. Bolus doses in the range of 625 mg to 2.5 g (12.5-50 mg/kg) have been fatal. Patients have recovered completely from overdoses as high as 1.75 g given over one minute or doses of 7.5 g given over one hour for cardiovascular surgery. The patients who survived appear to be those whose circulation could be supported until the effects of esmolol hydrochloride resolved.

Because of its approximately 9-minute elimination half-life, the first step in the management of toxicity should be to discontinue the esmolol hydrochloride infusion. Then, based on the observed clinical effects, the following general measures should also be considered.

Bradycardia: Intravenous administration of atropine or another anticholinergic drug.

Bronchospasm: Intravenous administration of a beta2 stimulating agent and/or a theophylline derivative.

Cardiac Failure: Intravenous administration of a diuretic and/or digitalis glycoside. In shock resulting from inadequate cardiac contractility, intravenous administration of dopamine, dobutamine, isoproterenol, or amrinone may be considered.

Symptomatic Hypotension: Intravenous administration of fluids and/or pressor agents.
Disclosed in the present application is a method for preparing a Gentiana macrophylla Pall. extract, comprising the following steps: taking Gentiana macrophylla Pall., adding an extraction solvent for extraction, loading the obtained extract solution on a macroporous adsorption resin chromatography column for separation and purification, collecting the eluate, concentrating, and drying, to obtain the Gentiana macrophylla Pall. extract. The macroporous adsorption resin is formed by mixing two types of resins, HP20 and AB-8. The advantage of the present application is: gentiopicroside and loganic acid can be effectively extracted from the Gentiana macrophylla Pall., to obtain the Gentiana macrophylla Pall. extract having barrier repair, anti-inflammatory, soothing and nerve sedative effects.
1,159,529. Dialkoxycarbonylthiamines. SHIONOGI & CO. Ltd. 30 May, 1967 [31 May, 1966], No. 24910/67. Addition to 944,641. Heading C2V. O,S-Dialkoxycarbonylthiamines (as described in Specification 944,641) are prepared by reacting an S-alkali metal salt of thiol type thiamine with 1À0 to 1À2 mol. equivalent of an alkyl chlorocarbonate in an aqueous medium or a mixed medium of water and an organic solvent to obtain an S-alkoxy carbonylthiamine, reacting the S-alkoxycarbonylthiamine with 1À0 to 1À2 mol. equivalent of an alkali metal hydroxide in an aqueous medium or mixed medium of water and an organic solvent to obtain an S- alkali metal salt of O-alkoxycarbonylthiamine and then reacting the S-alkali metal salts of O-alkoxycarbonylthiamine with 1À0 to 1À2 mol. equivalent of alkyl chlorocarbonate in an aqueous medium or a mixed medium of water and an organic solvent. Alternatively, the starting material may be an S-alkoxycarbonylthiamine which is reacted first with alkali metal hydroxide as above to obtain the salt of the O- alkoxycarbonylthiamine, and this is reacted with the alkyl chlorocarbonate as above to obtain the O,S-dialkoxycarbonylthiamine compound. In examples, the starting materials are the sodium and potassium salts of thiol type thiamine, S-ethoxycarbonylthiamine, S-nbutoxycarbonylthiamine and S-methoxycarbonylthiamine, and the other reactants are sodium and potassium hydroxide, ethyl chlorocarbonate, methyl chlorocarbonate and n-butyl chlorocarbonate.
FIELD: medicine. SUBSTANCE: desired sulfatized N,O-hepatosans comprises chains or their mixture having molecular weight 1500-15000 has repeated disaccharide structure I given in specification. In said formula E is acetyl group, its quantity being 0-60 % of disaccharide units of N,O-sulfatized hepatosans, the rest disaccharide units comprise sulfate group and if it is necessary, hydrogen atom; G is hydrogen or sulfate group; degree of sulfatization of hepatosans (being expressed as ratio of sulfate and carboxyl) is 1.9-3. Compound having formula I is prepared by consequent steps, namely: a) cultivation of Escherichia coli strain; b) isolation and purification of N-acetylheparosan to prepare composition comprising 70-100 % of heparosan; c) partially deacetylation thus prepared composition; d) partially or complete N,O-sulfatization thus prepared composition. EFFECT: improved quality of desired product. 29 cl, 18 tbl
Patients will receive hyperthermic intraperitoneal chemotherapy (HIPEC) during laparoscopic staging. Then 3 cycles of preoperative chemotherapy and clinical evaluation of chemotherapy will be performed. If the patient's disease is evaluated as progressed, the patient will receive systemic therapy. If it's stable or remission, a second time laparoscopic staging and peritoneal cytology examination will be performed. If peritoneal implant is observed, the patients will receive systemic therapy. If the peritoneal cytology is still positive, the treatment will be decided according to the suggestion of MDT discussion. If the peritoneal cytology is converted negative, standard gastrectomy with D2 lymphadenectomy and extensive intraperitoneal lavage (EIPL) will be performed. Postoperative chemotherapy will be determined according to the pathological evaluation of preoperative chemotherapy response.
The present invention relates to medicine for treating burns, scalds and injuries, namely ointment for burns and scalds. The ointment has the medicine components of the following proportion by weight: 10 to 50g of astragalus root, 10 to 50g of sanguisorba root, 10 to 50g of scorpion, 10 to 50g of myrrh, 10 to 50g of dahurian angelica root, 10 to 50g of borneol, 10 to 50g of antibiotics and 10 to 500g of adhesive. The medicine prepared by the proposal of the medicine has the functions of rapid inflammation elimination, pain alleviation, hemostasis, blood circulation promotion, rotted tissue removal and muscle regeneration. By a trial, the medicine of the medicine can be used by smearing for curing patients with general burns and scalds below the third degree for only 15 days or so. In addition, no scar remains, and less pigmentation exists. The elasticity and the mobility of skins are the same as the elasticity and the mobility of original skins. The medicine is the new generation of recovery therapeutic medicine for curing burns, scalds and injuries.
A nucleic acid (NA) or its parts hybridisable with the shown nucleotide sequences for a human lymphocyte activation gene CD30 are claimed. Also claimed are (i) poly- or oligonucleotides produced in vitro, (ii) a NA modified with detectable markers, (iii) vectors contg. the NA, (iv) host cells, pref. eukaryotic host cells, transformed with (iii), (v) native and mature CD30-antigens or fragments thereof, (vi) prod. methods of CD30, (vii) uses of CD30 molecules as immunogenic substances or as factors in cell cultures, (viii) uses of CD30 as standards in antibody based methods, and (ix) DNA of DSM 6833. USE - CD30 can be used for the identification of anaplastic large cell neoplasm (large cell lymphomas), for the diagnosis of Hodgkins disease and for the prodn. of transgenic animals
Participants will consume 1 gram of ACCS100 at each meal (up to three times per day) for seven days. The ACCS100 will be administered by mixing a powder sachet into water.
Glenohumeral osteoarthritis (GOA) is characterized by chronic inflammation leading to joint damage. Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) are promising therapies because of their immunomodulatory functions. The anti-inflammatory effects of EVs from human Adipose-derived MSCs (hADSCs) overexpressing microRNA (miR)-146a were investigated in experimental GOA in this study. hADSCs were transfected with a mimic negative control or miR-146a mimics. GOA was induced in C57/Bl6j mice, and subsequently, the animals were treated intra-articularly with phosphate-buffered saline, miR-146a EVs, or miR-control EVs. The expression of miR-146a and its targeted cytokines interleukin (IL)-4, IL-10, tumor necrosis factor-alpha (TNF-α), IL-17, and interferon-gamma (IFN-γ) were analyzed in the spleen of mice by enzyme-linked immunosorbent assay and in the articular cartilage by real-time polymerase chain reaction. miR-146a EVs showed enrichment of miR-146a. In GOA mice, miR-146a EV treatment significantly reduced expression levels of inflammatory cytokines IFN-γ, IL-17, and TNF-α and increased the anti-inflammatory cytokine IL-10 and IL-4 compared to controls. miR-146a EV treatment raised the anti-inflammatory cytokines and reduced the pro-inflammatory cytokines of the spleen in treated mice. This study demonstrates that EVs derived from hADSCs overexpressing miR-146a have enhanced anti-inflammatory potential in GOA by modulating cytokine expression and production. EVs engineered with inflammation-related miRNAs could be a cell-free therapeutic approach for GOA.
With the escalating prevalence of hair loss, the demand for effective hair loss treatment has surged. This study evaluated the effects of hot water extract of Hydrangea serrata (Thunb.) Ser. leaf (WHS) on hair growth, employing cell cultures, mice, and human skin organoid models. Both WHS and hydrangenol were found to enhance 5α-reductase inhibitory activity. WHS and hydrangenol have been shown to stimulate dermal papilla cell (DPC) growth, potentially through factors like keratinocyte growth factor (KGF), fibroblast growth factor 10 (FGF10), and transforming growth factor-β1 (TGF-β1). They also elevated the expression levels of keratin genes (K31 and K85) and the ceramide synthase (CerS3) gene, crucial clinical indicators of hair health. Furthermore, they exhibited notable anti-inflammatory and anti-androgenic properties by reducing the levels of tumor necrosis factor-α (TNF-α) and androgen signaling molecules, including androgen receptor (AR) and dickkopf-1 (DKK-1) gene expression. Oral administration of WHS to C57BL/6 mice for 3 weeks confirmed its hair growth-promoting effects, improving hair growth parameters and gene expression without significant changes in hair weight. Additionally, in a human skin organoid model, WHS was found to stimulate hair formation and augment the expression of follicle markers. These findings position WHS as a promising nutraceutical for promoting hair health, as evidenced by its efficacy in both in vitro and in vivo models.
The dose expansion part of the study will begin after completion of the dose escalation phase and will consist of 3 cohorts of 14 subjects each. One taxane-resistant tumor type will be evaluated in each cohort.
Immune nephritis is a chronic glomerular disease originating in the kidney caused by various etiologies.Clinically, secondary chronic kidney damage caused by systemic diseases such as diabetes, systemic lupus erythematosus and gout is named after its primary disease, such as diabetic nephropathy and lupus nephritis. Autoimmune diseases only show local pathological damage, but more often systemic lesions. If not diagnosed and treated in time or poorly controlled, a risk of disability or even death as the course of the disease progresses. Studies have shown that B cells can present their own antigens to autoimmune T cells to promote the release of inflammatory factors, or they can differentiate into plasma cells to release autoantibodies, and play an important role in the occurrence and progression of autoimmune diseases. In recent years, it has become a major research focus to deplete B cells in patients or inhibit B cell function. This research focuses on CAR-T cells killing B cells.

Based on the current research progress, our center intends to conduct research on the safety and effectiveness of CD19/BCMA CAR-T cells in the treatment of refractory systemic lupus erythematosus.
The invention discloses preparation of pidotimod sodium and medicinal application thereof. The pidotimod sodium is used for treating: (1) recurrent upper and lower respiratory tract infections (pharyngitis, tracheitis, bronchitis and tonsillitis); (2) repeated infections of E.N.T.department (rhinitis, nasosinusitis and otitis); (3) urinary system infections; (4) gynae infections; (5) clinical patients with cellular immune hypofunction after chemo-treatment; and (6) specific and non specific immunity deficiency diseases, such as cancer. The pidotimod sodium is used for reducing the times of acute attacks, shortening course of disease, relieving degree of attack, and can also be used as adjuvant therapy of antibiotic during acute infections. The pidotimod sodium is obtained through concentrating and drying, or adding insoluble organic solvent for crystallization, or freezing and drying after pidotimod reacts with sodium hydroxide in water or ethanol (but not limited to the solvents). The pidotimod sodium and various pharmaceutically accepted excipients to prepare various pharmaceutically accepted preparation formulations, including but not limited to tablets, capsules, injections and the like, in particular to infusion solution which is used for intravenously administration and is prepared from the pidotimod sodium, and injection, menstruum crystal split powder injection and freeze-drying powder injection which can be added to injection of 5 percent glucose or injection of 0.9 percent sodium chloride. The pidotimod sodium prepared by the method has large solubility in water, and improves the stability of the pidotimod. When the pidotimod is prepared into injection, pH value of the injection is more approximate to pH value of human body.
PURPOSE: A method for producing microemulsion containing amphotericin B by solubilizing amphotericin B using vitamin C is provided. Thus, intravenous injection including the microemulsion has enhanced stability and safety to human body. CONSTITUTION: Microemulsion contains 0.1 to 10 parts by weight of amphotericin B, based on 100 parts by weight of an oil phase. To produce the microemulsion, vitamin C and amphotericin B are dissolved in an oil phase at 60 to 80deg.C, and vitamin C is dissolved in a water phase. Thereafter, the oil phase where amphotericin B is dissolved is dispersed in the water phase where vitamin C is dissolved. The oil phase contains one or more organic solvent selected from ethyl oleate, propylene glycol, dimethylacetamide and glycol.
The present invention relates to a method for fixing Chinese medicinal bone-setting paper. Bone-setting powder which is a Chinese medicinal preparation prepared according to a proportion by weight is put in a container, and egg white is added for uniform mixing to form paste. The liquid medicine is uniformly coated on jute paper by a hair brush, and a layer of the liquid medicine is coated on each piece of the jute paper in sequence for use. After a fracture site is reset by a Chinese medical method, the prepared medicinal paper is spread at the affected part and tightly and fixedly bounded by a bandage. The medicinal paper can be dried in 24 hours, and the hardness approximates to that of gypsum. The Chinese medical bone-setting powder is prepared from angelica, chuanxiong rhizome, eucommia bark, rhizoma drynariae, pyrite, himalayan teasel root, olibanum, myrrh, musk, silktree albizzia bark and williams elder twig according to a proportion by weight. In the present invention, fixed materials and medicines are combined. Thereby, the present invention has the dual effects on the fixation of fracture and the permeation of medicines at affected parts for promoting the union of fracture, has the advantages of reliable fixation, short course of the treatment, significant curative effect and low therapeutic expense, can contour any part of a human body and is suitable for treating various fractures.
The invention discloses an artificial intelligent auxiliary diagnosis and treatment decision system based on a bladder non-urinary tract Pi Ai subtype. The system comprises a picture acquisition subsystem, a color processing subsystem, a shape processing subsystem, a combination processing subsystem and an output processing subsystem. The system improves the diagnosis accuracy of pathological diagnosis staff on bladder non-urothelial cancer through artificial intelligent learning. After surgery, the system analyzes HE stained pathological sections, certifying the bladder cancer area. Then, the system identifies bladder non-urothelial cancer area images with different outlines, deeply processes and synthesizes the images, becomes the input of an artificial intelligent authentication model, and outputs an authentication result. The identification result of the multi-layer region provides assistance for pathological diagnosis personnel, and the identification result of the multi-layer region of the bladder non-urothelial cancer is described. The system aims at preprocessing the slice by a technical means, finding the AI identification signal and helping to improve the accuracy of pathological diagnosis.
Emergence delirium has been described as a dissociated state of consciousness in which the child is irritable, uncompromising, uncooperative, incoherent, inconsolably crying, moaning, kicking or thrashing. The children can run the gambit from restlessness and incoherence to combative and psychotic. The incidence of emergence agitation or delirium is 80% after a procedure with sevoflurane-induced anesthesia.

Dexmedetomidine has been shown to have sedative and analgesic effects. In the pediatric population, it has been shown to provide sedation for radiographic procedures. Intravenously, it is has been shown to decrease emergence delirium following sevoflurane based anesthesia. The ability to administer a medication intranasally might solve the problem of emergence delirium and emergence agitation posed by the young patients undergoing myringotomy and tube placement.